Wikipedia

Ari Melnick

Ari Melnick is an Argentine-born physician and biomedical researcher specialising in haematological malignancies and cancer epigenetics.[1][2] Since 2025, he is the Director of the Josep Carreras Leukaemia Research Institute in Spain.[3]

Ari Melnick

Education

edit

Melnick studied medicine at the University of Buenos Aires, graduating in 1990. He subsequently continued his professional and academic career in the United States.[4][5]

Career

edit

Melnick has held positions at the Mount Sinai School of Medicine in New York and later joined Weill Cornell Medicine. At Weill Cornell he directs the Haematologic Malignancies Research Program, a role he has combined since 2013 with his appointment as Gebroe Family Professor of Haematology/Oncology. In 2025 he was appointed Director of the Josep Carreras Leukaemia Research Institute.[4]

Research

edit

Melnick is an international reference in the fields of blood cancers and cancer epigenetics.[6][7] He played a leading role[8] in one of the first large-scale epigenomic studies in humans.[9] Through this and subsequent research, Melnick and collaborators demonstrated that aberrant epigenetic programming is a hallmark of cancer[10] and that epigenetic diversity contributes significantly[11] to tumour fitness and unfavorable patient outcomes.[2][1][3]

His therapeutic approaches have been approved by the United States Food and Drug Administration or advanced to phase III clinical trials.[2][1]

Awards and honours

edit

In recognition of his contributions to translational research in haematology, Melnick received the Ernest Beutler Prize in Translational Research from the American Society of Hematology.[3][12]

Melnick is a member of the Board of Directors of the Leukemia and Lymphoma Society and the Lymphoma Research Foundation.[3]

References

edit
  1. 1 2 3 "Ari Melnick". Melnick Lab. Retrieved 2025-11-01.
  2. 1 2 3 "A new chapter in leukaemia and hematologic disease research". healthcare-in-europe.com. Retrieved 2025-11-01.
  3. 1 2 3 4 "Ari Melnick sustituye a Manel Esteller como director del Instituto de Investigación Josep Carreras". La Vanguardia (in Spanish). 2025-04-22. Retrieved 2025-11-01.
  4. 1 2 "Director". www.carrerasresearch.org. Retrieved 2025-11-05.
  5. ↑ "Playing the Long Game in Lymphoma Research". Lymphoma Research Foundation. Retrieved 2025-11-07.
  6. ↑ "Melnick, Ari M." vivo.weill.cornell.edu. Retrieved 2025-11-07.
  7. ↑ "Ari Melnick". Melnick Lab. Retrieved 2025-11-07.
  8. ↑ "ORCID". orcid.org. Retrieved 2025-11-07.
  9. ↑ Chambwe, Nyasha; Kormaksson, Matthias; Geng, Huimin; De, Subhajyoti; Michor, Franziska; Johnson, Nathalie A.; Morin, Ryan D.; Scott, David W.; Godley, Lucy A.; Gascoyne, Randy D.; Melnick, Ari; Campagne, Fabien; Shaknovich, Rita (2014-03-13). "Variability in DNA methylation defines novel epigenetic subgroups of DLBCL associated with different clinical outcomes". Blood. 123 (11): 1699–1708. doi:10.1182/blood-2013-07-509885. ISSN 1528-0020. PMC 3954051. PMID 24385541.
  10. ↑ Duy, Cihangir; Béguelin, Wendy; Melnick, Ari (2020-12-01). "Epigenetic Mechanisms in Leukemias and Lymphomas". Cold Spring Harbor Perspectives in Medicine. 10 (12) a034959. doi:10.1101/cshperspect.a034959. ISSN 2157-1422. PMC 7706582. PMID 32014848.
  11. ↑ Teater, Matt; Dominguez, Pilar M.; Redmond, David; Chen, Zhengming; Ennishi, Daisuke; Scott, David W.; Cimmino, Luisa; Ghione, Paola; Chaudhuri, Jayanta; Gascoyne, Randy D.; Aifantis, Iannis; Inghirami, Giorgio; Elemento, Olivier; Melnick, Ari; Shaknovich, Rita (2018-01-15). "AICDA drives epigenetic heterogeneity and accelerates germinal center-derived lymphomagenesis". Nature Communications. 9 (1): 222. Bibcode:2018NatCo...9..222T. doi:10.1038/s41467-017-02595-w. ISSN 2041-1723. PMC 5768781. PMID 29335468.
  12. ↑ "2020 Ernest Beutler Lecture and Prize Presented to Ari Melnick, MD, and Courtney DiNardo, MD". The ASCO Post. December 10, 2020. Retrieved 2025-11-07.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Ari_Melnick&oldid=1350474870"